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Background: Rhodococcus equi is an important pulmonary pathogen in foals and in immunocompromised individuals.
Virulent R. equi strains carry an 80-90 kb virulence plasmid that expresses the virulence-associated protein A (VapA).
VapA expression is regulated by temperature and pH. The LysR-type transcriptional regulator, VirR, is involved in
the regulation of the vapA gene. To examine the mechanism underlying transcriptional regulation of vapA, we
characterized an R. equi mutant in which another putative transcriptional regulator encoded on the virulence
plasmid, VirS, was deleted.
Results: Deletion of virS reduced vapA promoter activity to non-inducible levels. Complementary expression of VirS in
the virS deletion mutant restored transcription at the PvapA promoter, even under non-inducing conditions
(30°C and pH 8.0). In addition, VirS expression increased PvapA promoter activity in the absence of functional
VirR. Further, transcription of the icgA operon containing virS was regulated by pH and temperature in the same
manner as vapA.
Conclusions: This study suggests that VirS is required for VapA expression and that regulation of PvapA-promoter
activity may be achieved by controlling VirS expression levels.
Keywords: Opportunistic infections, Rhodococcus equi, Rhodococcus equi VapA protein virulence, VirSBackground
Rhodococcus equi is a Gram-positive bacterium and a
facultative intracellular pathogen of alveolar macro-
phages. Rhodococcus equi can cause bronchopneumonia
in foals up to five months of age [1,2]. This bacterium
has further been identified as an opportunistic pathogen
in individuals compromised by immunosuppressive drug
therapy, lymphoma, or acquired immunodeficiency syn-
drome (AIDS) [3-6].
Isolates from pneumonic foals possess a large plasmid
that varies in size from 80 to 90 kb [7-9]. This plasmid is
present in most clinical R. equi isolates recovered from
infected foals but it is absent from most environmental
strains [10]. Importantly, plasmid-cured isogenic mu-
tants of virulent strains lose their ability to survive in
macrophages and are unable to cause pneumonia in* Correspondence: kakuda@vmas.kitasato-u.ac.jp
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unless otherwise stated.foals [11-14]. A highly immunogenic 15–17 kDa protein
of unknown function, designated as virulence-associated
protein A (VapA), is encoded within a pathogenicity is-
land of this virulence plasmid [15]. VapA is essential for
intracellular growth in macrophages and for full viru-
lence in an infected mouse model [16].
The expression of vapA is controlled by temperature
and pH, where maximum expression occurs at 34–41°C
with a pH of 5.0 [17,18]. These characteristics suggest that
vapA expression is intracellularly upregulated in the mam-
malian host. Indeed, transcription of vapA is increased in
ex vivo murine and equine macrophages [19]. Further-
more, expression of VapA can be detected in macrophages
recovered from pulmonary lesions of infected foals [20].
The virR gene encodes a LysR-type transcriptional
regulator that affects vapA gene expression [21]. DNA
binding studies have shown that VirR binds to a DNA
fragment that contains the vapA promoter (PvapA). VirR
alone can induce vapA expression, but VapA expression
is enhanced when four genes downstream of virR areLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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tein that shares homology with the OmpR/PhoB family
of response regulators [22]. It has not yet been demon-
strated whether VirS is involved in the regulation of the
PvapA-promoter activity.
In the present study, we constructed a virS deletion
mutant and analyzed PvapA promoter activity using a
R. equi strain that harbored a PvapA-lacZ fusion viru-
lence plasmid. Our results suggest that VirS contributes
to the regulation of vapA transcription, and is thus a
critical component of R. equi virulence.
Methods
Bacterial strains and culture conditions
The R. equi ATCC33701 strain, originally isolated from
a pneumonic foal, was used as the genetic backgroundTable 1 Bacteria and plasmids used in this study
Bacterial species and plasmids Bacterial strains and plasmid names R





























pTKR528 pfor all experiments reported in this study. Rhodococcus
equi was routinely grown on Luria–Bertani (LB) agar at
30°C. Apramycin (60 μg/mL) was added to LB agar to
select for R. equi growth when necessary. All R. equi
strains were stored at −80°C in 85% LB broth/15% gly-
cerol (vol/vol). Escherichia coli DH5α was grown on
LB agar or in LB broth. Antibiotics were used when ne-
cessary at the following concentrations: apramycin
(60 μg/mL) or ampicillin (50 μg/mL). All E. coli strains
were stored at −80°C in 85% LB broth/15% glycerol
(vol/vol). Table 1 describes all strains and plasmids
used in this study.
Western blot analysis
Cell extracts were boiled for 5 min in sodium dodecyl
sulfate (SDS) solution (62.5 mM Tris–HCl [pH 6.8], 10%elevant characteristics Source or reference
irulent strain
vapA-lacZ fusion strain of ATCC33701 This study
virS of TKR255 This study
irRΔHTH of TKR255 This study
-, Φ80dlacZΔM15, Δ(lacZYA-rgF)U169, deoR, recA1, endA1, hsdR17(rK-, mK+),
hoA, supE44, λ-, thi-1, gyrA96, relA1
mpr
Bluescript::aac(3)IV This study






GEM, 3.5 kb fragment containg vapA This study
vapA (codon4-189) of pTKR130 This study
TKR139::lacZ This study
Dela::PvapA-lacZ This study
GEM, 3.9 kb fragment containg virR This study
GEM, 3.9 kb fragment containg virS This study
apRΔHTH(codon2-50) of pTKR333 This study
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mercaptoethanol, and 0.02% [wt/vol] bromophenol
blue). SDS-polyacrylamide gel electrophoresis was per-
formed using a 15% polyacrylamide gel according to
the method described previously by Laemmli [24]. After
electrophoresis, proteins were transferred to a nitrocellu-
lose membrane (Protoran; GE Healthcare, Piscataway,
NJ, USA), according to the manufacturer’s instructions. A
monoclonal antibody against VapA (Mab10G5) was used
for immunoblotting procedures [25].
Plasmid construction
To construct mutants with unmarked in-frame gene
deletions within R. equi, a plasmid containing the codA-
upp cassette was constructed to facilitate positive selection
of targeted gene deletion mutants. Briefly, an apramycin
resistance gene [aac(3)IV] was synthesized and cloned into
pUC57at the EcoRI and HindIII sites. Next, the apramycin
resistance gene cassette was excised by digestion with
EcoRI and HindIII, then cloned into pBluescript II SK(+)
digested with EcoRI and HindIII to create pTKR131. oriT
was amplified from pEco101 by polymerase chain reac-
tion (PCR) using primers oriT-F and oriT-R. The PCR
product was digested with SpeI and EcoRI, and cloned
into pTKR131 digested with SpeI and EcoRI to create
pTKR144. The aphII promoter (PaphII) region was amp-
lified using primers aph2-F and aph2-R. The amplified
DNA fragment was digested with HindIII and ClaI, and
cloned into pTKR144 digested with HindIII and ClaI to
create pTKR159. Finally, the codA-upp cassette was ex-
cised from pORF-codA-upp (InvivoGen, San Diego, CA,
USA) by digesting with NcoI and HindIII, and then
cloned into pTKR159 digested with NcoI and HindIII to
create pDelta. Primers used in this study are listed in
Additional file 1: Table S1.
A plasmid containing the Streptomyces ϕC31 integrase
gene was constructed to generate the integration vector
for the complementation experiments [26]. The ϕC31
integrase gene flanked by ApaI sites was synthesized and
cloned into pUC57 digested with EcoRV. The ϕC31 inte-
grase gene was excised with ApaI and cloned into
ApaI-digested pTKR131 to create pINT.
Construction of a vapA::lacZ fusion R. equi ATCC33701 strain
To construct the transcriptional fusion product contain-
ing the vapA promoter and the lacZ open reading frame
(ORF), the primer pair vapA-LF and vapA-LR was de-
signed according to the published sequence of pRE701
[22] and used for PCR amplification of a 3.5 kb fragment
that included approximately 1,500 nucleotides upstream
and downstream of vapA. This fragment was cloned into
the pGEM-T Easy vector (Promega, Tokyo, Japan) to
create pTKR130. PCR-mediated mutagenesis was used
to delete the vapA gene and to create BglII and MfeIsites within the coding sequence, and to produce
pTKR139 using pTKR130 as the template with the pri-
mer pair ΔvapA-1 and ΔvapA-2. The deleted region in
the vapA gene comprised codons 4–189. The promoter-
less lacZ gene was excised from pORF-lacZ (InvivoGen)
by digesting with BamHI and EcoRI, and then ligated
to pTKR139 digested with BclI and MfeI to create
pTKR148. The DNA fragment that contained the PvapA-
lacZ fusion was excised from pTKR148 by digesting with
EcoRI, and then ligated to EcoRI-digested pDelta to create
pTKR169. pTKR169 was electroporated into R. equi
ATCC33701 as described previously [27]. Transformants
(single crossovers) were selected on LB agar containing
apramycin (60 μg/mL). 5-Fluorocytosine (5-FC) positive
selection was performed as described previously [28].
Briefly, R. equi transformants were inoculated into LB li-
quid medium and grown overnight at 30°C. 5-FC selection
of double crossovers was performed by plating 100-μL ali-
quots of a dilution series [10−1 to 10−3 in mineral acetate
(MM-Ac) medium] of the culture onto MM-Ac agar
plates supplemented with 5-FC (100 μg/mL). Plates were
incubated at 30°C for 2–3 days. Virulence plasmids were
isolated from 5-FC-resistant and apramycin-sensitive mu-
tants, and analyzed by digestion with EcoRI. Mutants that
produced the expected digestion pattern were selected
(Additional file 2: Figure S1). The mutated locus was fur-
ther analyzed by PCR and sequencing. One mutant strain
was selected, designated TKR255, and used for further
characterization.
Construction of R. equi ΔvirS and virRΔHTH strains
harboring the PvapA-lacZ fusion
To construct in-frame virR and virS deletion mutants,
3.9 kb and 3.8 kb fragments including approximately
1,500 nucleotides upstream and downstream of virR and
virS, respectively, were amplified by PCR using the pri-
mer pairs virR-LF and virR-LR, and virS-LF and virS-LR.
These fragments were cloned into the pGEM-T Easy vec-
tor to create pTKR333 and pTKR223. PCR-mediated mu-
tagenesis was employed to delete the virR and virS genes
using primer pairs ΔvirR-1 and ΔvirR-2, and ΔvirS-1 and
ΔvirS-2, respectively. pTKR333 and pTKR223 were used
as templates to create pTKR361 and pTKR226, respect-
ively. The deleted region in the virR gene comprised co-
dons 2–50 (virRΔHTH). The deleted region in the virS gene
comprised codons 2–252. Fragments that contained ΔvirS
and virRΔHTH were excised from pTKR361 and pTKR226
by EcoRI digestion and ligated to EcoRI-digested pDelta to
create pTKR265 and pTKR391, respectively. pTKR265
and pTKR391 were separately electroporated into the
PvapA-lacZ strain (TKR255), and the ΔvirS and virRΔHTH
mutants (TKR303 and TKR474, respectively) were se-
lected and confirmed as described above (Additional file 3:
Figure S2 and Additional file 4: Figure S3).
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The virS ORF was amplified using the primer pair virS-
NcoF and virS-HindR. The PCR product was digested
with NcoI and HindIII, and cloned into pTKR174
digested with NcoI and HindIII to create pTKR340.
pTKR340 was digested with NotI and ligated to NotI-
digested pINT to create pTKR344. pTKR344 was
electroporated into TRK303. The transformants were
recovered on LB agar containing 60 μg/mL apramycin.
PCR-mediated mutagenesis was used to introduce point
mutations into the coding sequence of virS in pTKR344,
and pTKR445 (pINT::virSD57A) was produced using
the primer pair virS D57A-1 and virS D57A-2. This
plasmid was electroporated into TKR303. Transfor-
mants were recovered on LB agar containing 60 μg/mL
apramycin.
The fragment that contained the virR ORF and promoter
region was amplified using the primer pair PvirR-F and
virR-R. The DNA fragment was cloned into the pGEM-T
vector to create pTKR509. pTKR509 was digested with
NotI and ligated to NotI-digested pINT to create pTKR528.
pTKR528 was electroporated into TKR474. Transformants
were recovered on LB agar containing 60 μg/mL
apramycin.
β-Galactosidase assays
Cells were grown overnight at 30°C in brain-heart infu-
sion (BHI) broth with shaking. Cultures were diluted to
1: 10 with 60 mM Tris-buffered BHI, and the pH was
adjusted to pH 6.5 or pH 8.0. Cultures were grown until
they reached an optical density at 600 nm (OD600) of
0.5–0.7. Cells were washed twice with 0.9% NaCl and re-
suspended in 500 μL Z buffer (60 mM Na2HPO4,
40 mM NaH2PO4, 10 mM KCl, 1 mM MgSO4, 50 mM
β-mercaptoethanol, pH 7.6) [29]. Next, cells were perme-
abilized by adding 20 μL chloroform and 35 μL 0.1% SDS.
One hundred microliters of 13 mM 2-nitrophenyl beta-D-
galactopyranoside (Sigma-Aldrich, St Louis, MO, USA)
was added to each sample, followed by incubation at 28°C
for 5 min. The reaction was stopped by adding 250 μL
1 M Na2CO3, and absorbance was read at 420 nm using a
spectrophotometer (GENESYS 20; Thermo Fisher Scien-
tific, Waltham, MA, USA). The activity of each sample
was calculated in Miller units as follows: 1,000 ×OD420/
OD600 × reaction time × volume. Assays were performed
in triplicate at least three times. Graphs were created using
GraphPad PRISM software.
Transcriptional analysis of the operon containing virS
Total bacterial RNA was isolated from 5 mL cultures
grown to the mid-logarithmic phase (OD600 = 0.25).
Next, 10 mL of RNAprotect Bacteria Reagent (Qiagen,
Hilden, Germany) was added to the bacterial cultures,
immediately mixed, and incubated for 5 min at roomtemperature. Cells were harvested by centrifugation for
10 min at 5,000 × g at 4°C. Following this, cells were
resuspended in 1 mL of RLT buffer (RNeasy Mini Kit;
Qiagen) and added to 0.5 mL of 0.1 mm diameter
zirconia-silica beads (μT-01; TAITEC, Saitama, Japan).
Samples were lysed three times for 1 min with a bead
beater (TAITEC) at 4,600 rpm. Total RNA was isolated
using an RNeasy RNA mini kit (Qiagen), according to
the manufacturer’s instructions. To eliminate DNA con-
tamination, RNA was treated with 10 U of RNase-free
DNase for 30 min at 37°C. DNase was inactivated by in-
cubating the mixture for 5 min at 75°C. Next, 200 ng
RNA was mixed with random 6-mers and cDNA was
synthesized using a PrimeScript RT–PCR kit (Takara,
Tokyo, Japan), according to the manufacturer’s instruc-
tions. Real-time RT-PCR analysis was performed in a 20-
μL volume that contained 1× PowerSYBR Green PCR
Master Mix (Applied Biosystems, Foster City, CA, USA),
200 nM forward and reverse primers, and the sample
cDNA. The primer pairs used to amplify vapH, orf7, and
virS were vapH-RTF and vapH-RTR, orf7-RTF, and orf7-
RTR, and virS-RTF and virS-RTR, respectively. Reactions
were performed with StepOne Real-Time PCR System
(Applied Biosystems) using the following conditions: 95°C
for 10 min, followed by 40 cycles at 95°C for 15 s and
60°C for 1 min. Results were normalized using 16S rRNA
as a control and analyzed with the ΔΔCT method. Graphs
were created using GraphPad PRISM software.Results
Development of a reporter system to analyze vapA gene
expression
Previous studies have reported that vapA gene expres-
sion is regulated by temperature and pH [17,18]. To con-
firm these regulatory effects, we performed western blot
analysis on cellular extracts of the R. equi ATCC33701
strain grown under four different conditions: 30°C at
pH 6.5, 30°C at pH 8.0, 37°C at pH 6.5, and 37°C at pH 8.0
(Figure 1A). Maximal expression of VapA occurred at 37°C
and pH 6.5. At 37°C and pH 8.0, VapA expression was
lower but still detectable. When bacteria were grown at
30°C; however, VapA expression was undetectable. To
measure the promoter activity of the vapA gene using a β-
galactosidase assay, we constructed a mutant strain wherein
the virulence plasmid contained a PvapA-lacZ fusion. The
highest β-galactosidase activity was detected when this
strain was grown at 37°C and pH 6.5 (Figure 1B). At 37°C
and pH 8.0, β-galactosidase activity was lower. Thus, these
results agreed with the results of the western blot analysis.
At 30°C, β-galactosidase activity was approximately 12-fold
lower than that at 37°C and pH 6.5. Importantly, these re-
sults indicated that this reporter strain could be used to
analyze vapA gene expression.
Figure 1 Regulation of vapA transcription and VapA expression
in R. equi. (A) Western blot analysis performed with an anti-VapA
antibody on cell extracts prepared from R. equi grown under conditions
indicated in the Figure (B) β-galactosidase activity assays of PvapA–lacZ
fusions in the R. equi TKR255 strain grown at different temperatures
and pH indicated in the Figure TKR255 was grown overnight at 30°C,
diluted to an OD60th0 of 0.05 in fresh medium at the pH indicated, and
incubated at the temperature indicated. β-galactosidase activity was
measured in Miller units and error bars represent standard deviations
for each data set (n = 3). Data were evaluated for statistical significance
using one-way ANOVA followed by the Dunnett’s multiple comparison
test, *p < 0.001.
Figure 2 Schematic of the virR and icgA operons. Open boxes
represent ORFs. Arrows indicate the transcript and its orientation.
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A previous study reported that VapA expression was
higher when four genes including virS were present in
addition to virR, when compared with virR alone (Figure 2)
[21]. To examine whether this increase could be attributed
to VirS, the virS gene was deleted from the virulence plas-
mid in the PvapA-lacZ fusion strain. In the ΔvirS mutant,
vapA promoter activity was reduced to a non-detectable
level (Figure 3). Complementation of the ΔvirS mutant
with virS expressed via from the PaphII promoter on the
bacterial chromosome increased PvapA-lacZ expression by
more than two-fold when this strain was grown under in-
ducing conditions. Moreover, when the complemented
mutant was grown at 30°C (under non-inducing condi-
tions), the transcription level of PvapA-lacZ was the sameas that of the strain grown under inducing conditions.
These results suggest that VirS is required for vapA ex-
pression and that vapA transcription can be induced if
VirS is expressed, even when grown under non-inducing
conditions.Phosphorylation of Asp57 is not required for the function
of VirS
Activation of OmpR/PhoB family response regulators re-
quires phosphorylation of a conserved aspartate residue
[30]. Interestingly, VirS contains an aspartate residue
(Asp57) that represents a putative phosphorylation site
(Figure 4). To determine whether Asp57 in VirS is ne-
cessary for VirS function, Asp57 was replaced with ala-
nine via site-directed mutagenesis. Transcription of
PvapA-lacZ in the virS (Asp57Ala) mutant was compar-
able to that of the strain expressing wild-type VirS
when they were both grown under inducing conditions
(Figure 3). These results suggest that the putative
phosphorylation site Asp57 is not necessary for VirS
function.VirS can increase PvapA promoter activity in the absence
of a functional VirR
Previous reports suggest that VirR is required for the
expression of both vapA and virS [21,31], and our re-
sults support the hypothesis that VirS can increase
vapA expression in the presence of virR. To examine
whether VirS function is VirR dependent, we con-
structed a virR deletion mutant. As the promoter of the
icgA operon containing virS is located within the virR
ORF (Figure 2), we did not delete the entire virR gene.
Instead, only the locus that corresponded to the helix-
turn-helix region (codons 2–50) was deleted and the
promoter of the icgA operon was kept intact. The
virRΔHTH mutation reduced the transcription level of
PvapA-lacZ to undetectable levels under non-inducing
conditions (Figure 3). When virS was expressed from
the chromosomal PaphII promoter in the virRΔHTH mu-
tant, the PvapA promoter was activated to comparable
levels detected in the presence of virR. These results
suggest that VirS can activate transcription of the PvapA
promoter in the absence of VirR.
Figure 3 β-Galactosidase activity assays of PvapA-acZ virS and virR deletion mutant strains. β-Galactosidase activity (measured in Miller
units) of the wild-type strain (TKR255), ΔvirS, pINT::PaphII-virS-integrated ΔvirS (PaphII-virS/ΔvirS), pINT::PaphII-virS (D57A)-integrated ΔvirS [PaphII-virS
(D57A)/ΔvirS], virRΔHTH, pINT::PvirR-virR-integrated virRΔHTH (PvirR-virR/virRΔHTH), and pINT::PaphII-virS-integrated virRΔHTH (PaphII-virS/virRΔHTH) strains grown
at pH 6.5 (lanes 1 and 3) or pH 8.0 (lanes 2 and 4). Error bars represent standard deviations for each data set (n = 3). Data were evaluated for
statistical significance using one-way ANOVA followed by the Dunnett’s multiple comparison test, *p < 0.001.
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temperature and pH
A previous study reported that transcription of the icgA
operon (Figure 2) was VirR dependent and was induced
at 37°C and pH 6.5 [31]. Although inducing (37°C at
pH 8.0) and non-inducing (30°C at pH 6.5) conditions
were compared, it was still not clear whether the tran-
scription of the icgA operon was regulated by temperature,
pH, or both. Thus, we semi-quantitatively determined the
transcriptional level of the icgA operon by real-time RT-
PCR. As shown previously, transcription of all the genes
in this operon was induced when the wild-type strain was
grown at 37°C and pH 6.5 (Figure 5A). However, their
transcriptional levels were lower when cells were
grown at 37°C and pH 8.0. Transcription was even
lower when cells were grown at 30°C. In agreement
with the previous study, we did not observe an increase
in the transcription of the icgA operon in the virRΔHTH
mutant (Figure 5B). These results demonstrate thatFigure 4 Primary sequence alignment of VirS and other OmpR/PhoB
between homologous proteins is highlighted by differences in shading: bla
the amino acids in a column are identical. The putative phosphorylation sit
conserved conformational switch residues (Thr87 and Tyr106) are indicated
aligned according to GENETYX-MAC software.transcription of the icgA operon is VirR dependent and
that it is regulated by both temperature and pH.
Discussion
Pneumonia-causing virulence by the bacterial pulmonary
pathogen R. equi has not been fully elucidated. However,
a previous study has demonstrated that VirR is involved
in the regulation of the vapA gene located on the R. equi
virulence plasmid [21]. To examine the contribution of
virS (located downstream of virR) to R. equi virulence and
the expression of VapA, we constructed an R. equi virS de-
letion strain paired with a PvapA-lacZ reporter virulence
plasmid. In the current study, we demonstrate that VirS is
another transcriptional regulator encoded on the virulence
plasmid that is required for vapA transcription.
With this work, we show that deletion of virS reduced
the transcriptional activation of the vapA promoter to
non-inducible levels. Further, previous studies have dem-
onstrated that virR is constitutively expressed and thatsubfamily members (E. coli CheY, PhoB, and OmpR). Similarity
ck, all amino acids in a column are identical; light gray, over half of
e (Asp57), conserved catalytic residues (Asp12, Asp13, and Lys109), and
by an asterisk, closed stars, and open stars, respectively. Proteins were
Figure 5 Effects of temperature and pH on PicgA promoter
activity. mRNA isolated from R. equi wild-type (A) and virRΔHTH
(B) strains were grown under the conditions indicated, followed by
semi-quantitative analysis of transcription using real-time RT-PCR.
Values represent the fold increase in expression relative to expression
in the wild-type grown at 30°C and pH 8.0. Data were evaluated for
statistical significance using one-way ANOVA followed by the Dunnett’s
multiple comparison test, *p < 0.001.
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gether, these data suggested that VirR expression would
be unaltered in a ΔvirS mutant, and that VirR alone is
not sufficient to activate the transcription of vapA in the
absence of VirS. In addition, deletion of virR completelyFigure 6 Proposed model of vapA transcriptional regulation in R. equ
by temperature and pH via unknown mechanisms. VirS activates transcriptiabolished vapA promoter activity. However, it has previ-
ously been demonstrated that VirR is required for VirS
expression [31]. Thus, we hypothesized that VirS has an
indirect effect on vapA gene transcription. Indeed, VirS
expression via the PaphII promoter restored expression of
the PvapA-lacZ fusion plasmid in the virRΔHTH mutant,
thereby supporting this hypothesis. Furthermore, when
VirS was expressed via the PaphII promoter, there was no
difference in transcription from the vapA promoter in
the presence or absence of VirR. These results indicate
that VirS can activate vapA transcription via the vapA
promoter in the absence of functional VirR.
Interestingly, chromosomal integration of the PaphII-
virS fusion did not restore PvapA-lacZ expression to
wild-type levels in the ΔvirS and virRΔHTH deletion mu-
tants. Furthermore, activation of the PvapA promoter was
observed under non-inducing conditions. It is possible
that expression of the PaphII-virS fusion, which was
present as a monocopy on the chromosome, may have
resulted in lower VirS expression levels when compared
with VirS expression from the virulence plasmid, as each
cell harbors two or more plasmid copies [32]. In addition,
this may have caused disordered regulation when VirS
was expressed from the PaphII promoter but not from the
original promoter found on the virulence plasmid.
VirS is an orphan response regulator, and its cognate
sensor is not found on the virulence plasmid [22]. VirS
can activate the PvapA promoter under non-inducing
conditions; thus, pH and temperature are unlikely to be
the stimuli that are responsible for VirS activation. We
further observed that the Asp57Ala mutation did not
affect activity of the PvapA promoter when compared
with that of wild-type VirS under inducing conditions.
These data suggest that this putative phosphorylation
site is not necessary for function of this domain.
Although most residues that are critical for canonical
functions in response regulators are well conserved in
VirS, Asp13, which chelates the Mg2+ necessary for aspar-
tic acid phosphorylation, is substituted with argininei. Transcription of the icgA operon is VirR dependent and is regulated
on of the vapA promoter.
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coli CheY protein means that it cannot chelate Mg2+ ef-
fectively and phosphorylation of Asp57 is blocked [30].
However, other OmpR/PhoB subfamily members such as
Myxococcus xanthus FrzS and Helicobacter pylori HP1043
retain their functional activity in the absence of phosphor-
ylation [36-38]. Therefore, VirS may be another atypical
response regulator that does not require a sensor protein
for activation.
In the present study, we demonstrated that the PicgA
promoter is regulated by both temperature and pH, and
this corresponds to regulation of the PvapA promoter.
Further, expression of VirS from the PaphII promoter
could induce the vapA transcription under non-inducing
conditions. These results suggest that regulation of vapA
by temperature and pH may be achieved by controlling
VirS expression levels, and a proposed model for this
regulation is presented in Figure 6. As such, mechanisms
that regulate expression of the icgA operon are likely
crucial in controlling vapA gene expression via environ-
mental stimuli in the bacterial pathogen R. equi.Conclusions
VirS is required for the expression of vapA, and VirS
expression is regulated by both temperature and pH.
We hypothesize that regulation of the PvapA promoter is
influenced by VirS expression levels. Future studies are
required to examine the mechanisms that regulate tran-
scription of the virS-containing icgA operon, and how
this operon contributes to R. equi virulence.Additional files
Additional file 1: Table S1. Primer used in this study.
Additional file 2: Figure S1. Construction of the R. equi vapA::lacZ
fusion strain by homologous recombination.
Additional file 3: Figure S2. Targeted mutagenesis of virS by
homologous recombination.
Additional file 4: Figure S3. Targeted mutagenesis of virR by
homologous recombination.Competing interest
The authors declare that they have no competing financial interests.
Authors’ contributions
Conceived and designed the experiments: TK, ST. Performed the
experiments: TH, TT, HH, SM, and TK. Data analysis: TK and ST. Contributed
reagents/materials/analysis tools: TK. Manuscript preparation: TK and ST. All
authors read and approved the final manuscript.
Acknowledgments
This research was partly supported by Grants-in-Aid for Scientific Research
(No. 24580452 to TK) from the Japan Society for the Promotion of Science.
Received: 15 May 2014 Accepted: 9 September 2014References
1. Takai S: Epidemiology of Rhodococcus equi infections: a review. Vet Microbiol
1997, 56:167–176.
2. Prescott JF: Rhodococcus equi: an animal and human pathogen. Clin Microbiol
Rev 1991, 4:20–34.
3. Takai S, Sasaki Y, Ikeda T, Uchida Y, Tsubaki S, Sekizaki T: Virulence of
Rhodococcus equi isolates from patients with and without AIDS. J Clin
Microbiol 1994, 32:457–460.
4. Takai S, Imai Y, Fukunaga N, Uchida Y, Kamisawa K, Sasaki Y, Tsubaki S, Sekizaki T:
Identification of virulence-associated antigens and plasmids in Rhodococcus
equi from patients with AIDS. J Infect Dis 1995, 172:1306–1311.
5. Takai S, Tharavichitkul P, Takarn P, Khantawa B, Tamura M, Tsukamoto A,
Takayama S, Yamatoda N, Kimura A, Sasaki Y, Kakuda T, Tsubaki S,
Maneekarn N, Sirisanthana T, Kirikae T: Molecular epidemiology of
Rhodococcus equi of intermediate virulence isolated from patients with
and without acquired immune deficiency syndrome in Chiang Mai,
Thailand. J Infect Dis 2003, 188:1717–1723.
6. Takai S, Tharavichitkul P, Sasaki C, Onishi Y, Yamano S, Kakuda T, Tsubaki S,
Trinarong C, Rojanasthien S, Sirimalaisuwan A, Tesaprateep T, Maneekarn N,
Sirisanthana T, Kirikae T: Identification of virulence-associated antigens
and plasmids in Rhodococcus equi from patients with acquired immune
deficiency syndrome and prevalence of virulent R. equi in soil collected
from domestic animal farms in Chiang Mai, Thailand. Am J Trop Med Hyg
2002, 66:52–55.
7. Takai S, Sekizaki T, Ozawa T, Sugawara T, Watanabe Y, Tsubaki S: Association
between a large plasmid and 15- to 17-kilodalton antigens in virulent
Rhodococcus equi. Infect Immun 1991, 59:4056–4060.
8. Takai S, Shoda M, Sasaki Y, Tsubaki S, Fortier G, Pronost S, Rahal K, Becu T,
Begg A, Browning G, Nicholson VM, Prescott JF: Restriction fragment
length polymorphisms of virulence plasmids in Rhodococcus equi. J Clin
Microbiol 1999, 37:3417–3420.
9. Takai S, Murata N, Kudo R, Narematsu N, Kakuda T, Sasaki Y, Tsubaki S:
Two new variants of the Rhodococcus equi virulence plasmid, 90 kb type III
and type IV, recovered from a foal in Japan. Vet Microbiol 2001, 82:373–381.
10. Takai S, Watanabe Y, Ikeda T, Ozawa T, Matsukura S, Tamada Y, Tsubaki S,
Sekizaki T: Virulence-associated plasmids in Rhodococcus equi. J Clin
Microbiol 1993, 31:1726–1729.
11. Hondalus MK, Mosser DM: Survival and replication of Rhodococcus equi in
macrophages. Infect Immun 1994, 62:4167–4175.
12. Wada R, Kamada M, Anzai T, Nakanishi A, Kanemaru T, Takai S, Tsubaki S:
Pathogenicity and virulence of Rhodococcus equi in foals following
intratracheal challenge. Vet Microbiol 1997, 56:301–312.
13. Giguere S, Hondalus MK, Yager JA, Darrah P, Mosser DM, Prescott JF: Role
of the 85-kilobase plasmid and plasmid-encoded virulence-associated
protein A in intracellular survival and virulence of Rhodococcus equi.
Infect Immun 1999, 67:3548–3557.
14. Toyooka K, Takai S, Kirikae T: Rhodococcus equi can survive a
phagolysosomal environment in macrophages by suppressing
acidification of the phagolysosome. J Med Microbiol 2005, 54:1007–1015.
15. Sekizaki T, Takai S, Egawa Y, Ikeda T, Ito H, Tsubaki S: Sequence of the
Rhodococcus equi gene encoding the virulence-associated 15–17-kDa an-
tigens. Gene 1995, 155:135–136.
16. Jain S, Bloom BR, Hondalus MK: Deletion of vapA encoding Virulence
Associated Protein A attenuates the intracellular actinomycete
Rhodococcus equi. Mol Microbiol 2003, 50:115–128.
17. Takai S, Iie M, Watanabe Y, Tsubaki S, Sekizaki T: Virulence-associated 15- to
17-kilodalton antigens in Rhodococcus equi: temperature-dependent ex-
pression and location of the antigens. Infect Immun 1992, 60:2995–2997.
18. Takai S, Fukunaga N, Kamisawa K, Imai Y, Sasaki Y, Tsubaki S: Expression of
virulence-associated antigens of Rhodococcus equi is regulated by
temperature and pH. Microbiol Immunol 1996, 40:591–594.
19. Ren J, Prescott JF: Analysis of virulence plasmid gene expression of
intra-macrophage and in vitro grown Rhodococcus equi ATCC 33701.
Vet Microbiol 2003, 94:167–182.
20. Madarame H, Takai S, Morisawa N, Fujii M, Hidaka D, Tsubaki S, Hasegawa
Y: Immunohistochemical detection of virulence-associated antigens
of Rhodococcus equi in pulmonary lesions of foals. Vet Pathol 1996,
33:341–343.
21. Russell DA, Byrne GA, O’Connell EP, Boland CA, Meijer WG: The LysR-type
transcriptional regulator VirR is required for expression of the virulence
gene vapA of Rhodococcus equi ATCC 33701. J Bacteriol 2004, 186:5576–5584.
Kakuda et al. BMC Microbiology 2014, 14:243 Page 9 of 9
http://www.biomedcentral.com/1471-2180/14/24322. Takai S, Hines SA, Sekizaki T, Nicholson VM, Alperin DA, Osaki M, Takamatsu
D, Nakamura M, Suzuki K, Ogino N, Kakuda T, Dan H, Prescott JF: DNA
sequence and comparison of virulence plasmids from Rhodococcus equi
ATCC 33701 and 103. Infect Immun 2000, 68:6840–6847.
23. Wiesner RS, Hendrixson DR, DiRita VJ: Natural transformation of
Campylobacter jejuni requires components of a type II secretion system.
J Bacteriol 2003, 185:5408–5418.
24. Laemmli UK: Cleavage of structural proteins during the assembly of the
head of bacteriophage T4. Nature 1970, 227:680–685.
25. Takai S, Iie M, Kobayashi C, Morishita T, Nishio T, Ishida T, Fujimura T,
Sasaki Y, Tsubaki S: Monoclonal antibody specific to virulence-associated
15- to 17-kilodalton antigens of Rhodococcus equi. J Clin Microbiol 1993,
31:2780–2782.
26. Hong Y, Hondalus MK: Site-specific integration of Streptomyces PhiC31
integrase-based vectors in the chromosome of Rhodococcus equi.
FEMS Microbiol Lett 2008, 287:63–68.
27. Sekizaki T, Tanoue T, Osaki M, Shimoji Y, Tsubaki S, Takai S: Improved
electroporation of Rhodococcus equi. J Vet Med Sci 1998, 60:277–279.
28. van der Geize R, de Jong W, Hessels GI, Grommen AW, Jacobs AA,
Dijkhuizen L: A novel method to generate unmarked gene deletions in
the intracellular pathogen Rhodococcus equi using 5-fluorocytosine
conditional lethality. Nucleic Acids Res 2008, 36:e151.
29. Miller JH: Experiments in Molecular Genetics. Cold Spring Harbor, NY: Cold
Spring Harbor Laboratory Press; 1972.
30. Bourret RB, Hess JF, Simon MI: Conserved aspartate residues and
phosphorylation in signal transduction by the chemotaxis protein CheY.
Proc Natl Acad Sci U S A 1990, 87:41–45.
31. Byrne GA, Russell DA, Chen X, Meijer WG: Transcriptional regulation of the
virR operon of the intracellular pathogen Rhodococcus equi. J Bacteriol
2007, 189:5082–5089.
32. Rodríguez-Lázaro D, Lewis DA, Ocampo-Sosa AA, Fogarty U, Makrai L, Navas J,
Scortti M, Hernández M, Vázquez-Boland JA: Internally controlled real-time
PCR method for quantitative species-specific detection and vapA
genotyping of Rhodococcus equi. Appl Environ Microbiol 2006, 72:4256–4263.
33. Djordjevic S, Stock AM: Structural analysis of bacterial chemotaxis
proteins: components of a dynamic signaling system. J Struct Biol 1998,
124:189–200.
34. Zundel CJ, Capener DC, McCleary WR: Analysis of the conserved acidic
residues in the regulatory domain of PhoB. FEBS Lett 1998, 441:242–246.
35. Lewis RJ, Brannigan JA, Muchová K, Barák I, Wilkinson AJ: Phosphorylated
aspartate in the structure of a response regulator protein. J Mol Biol 1999,
294:9–15.
36. Fraser JS, Merlie JP Jr, Echols N, Weisfield SR, Mignot T, Wemmer DE,
Zusman DR, Alber T: An atypical receiver domain controls the dynamic
polar localization of the Myxococcus xanthus social motility protein FrzS.
Mol Microbiol 2007, 65:319–332.
37. Hong E, Lee HM, Ko H, Kim DU, Jeon BY, Jung J, Shin J, Lee SA, Kim Y, Jeon YH,
Cheong C, Cho HS, Lee W: Structure of an atypical orphan response
regulator protein supports a new phosphorylation-independent regulatory
mechanism. J Biol Chem 2007, 282:20667–20675.
38. Schär J, Sickmann A, Beier D: Phosphorylation-independent activity of
atypical response regulators of Helicobacter pylori. J Bacteriol 2005,
187:3100–3109.
doi:10.1186/s12866-014-0243-1
Cite this article as: Kakuda et al.: VirS, an OmpR/PhoB subfamily response
regulator, is required for activation of vapA gene expression in Rhodococcus
equi. BMC Microbiology 2014 14:243.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
